| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Thyroid Neoplasms | 12 | 2019 | 422 | 3.82 | Why? |
| Cytodiagnosis | 7 | 2019 | 104 | 2.13 | Why? |
| Thyroid Gland | 10 | 2019 | 516 | 2.09 | Why? |
| Biopsy, Fine-Needle | 12 | 2020 | 274 | 1.96 | Why? |
| Thyroid Nodule | 6 | 2018 | 70 | 1.80 | Why? |
| Papanicolaou Test | 2 | 2018 | 65 | 1.42 | Why? |
| Carcinoma, Papillary | 4 | 2019 | 76 | 1.20 | Why? |
| Adenoma | 2 | 2018 | 215 | 1.15 | Why? |
| Carcinoma | 2 | 2017 | 256 | 1.07 | Why? |
| Precancerous Conditions | 2 | 2019 | 108 | 0.86 | Why? |
| Vaginal Smears | 2 | 2018 | 89 | 0.86 | Why? |
| Sex Cord-Gonadal Stromal Tumors | 1 | 2019 | 3 | 0.80 | Why? |
| Adenocarcinoma, Follicular | 2 | 2018 | 21 | 0.79 | Why? |
| Neoplasms, Complex and Mixed | 1 | 2018 | 7 | 0.78 | Why? |
| Carcinoma, Neuroendocrine | 2 | 2017 | 57 | 0.78 | Why? |
| Enterobiasis | 1 | 2017 | 4 | 0.73 | Why? |
| Uterine Neoplasms | 1 | 2019 | 70 | 0.72 | Why? |
| Hepatitis | 1 | 2020 | 160 | 0.71 | Why? |
| Asphyxia | 1 | 2017 | 28 | 0.69 | Why? |
| Neurosecretory Systems | 1 | 2017 | 48 | 0.69 | Why? |
| Cervix Uteri | 1 | 2019 | 146 | 0.69 | Why? |
| Endocrine System | 1 | 2017 | 67 | 0.69 | Why? |
| Cervical Intraepithelial Neoplasia | 1 | 2018 | 114 | 0.68 | Why? |
| Cytological Techniques | 1 | 2017 | 79 | 0.67 | Why? |
| Digestive System Neoplasms | 1 | 2018 | 146 | 0.65 | Why? |
| DNA Mutational Analysis | 4 | 2019 | 581 | 0.59 | Why? |
| Neck | 1 | 2017 | 307 | 0.58 | Why? |
| Neuroendocrine Tumors | 1 | 2018 | 241 | 0.58 | Why? |
| Biomarkers, Tumor | 6 | 2019 | 1314 | 0.56 | Why? |
| B7-H1 Antigen | 1 | 2017 | 541 | 0.51 | Why? |
| Ovarian Neoplasms | 1 | 2019 | 465 | 0.50 | Why? |
| Uterine Cervical Neoplasms | 2 | 2018 | 842 | 0.50 | Why? |
| Cell Differentiation | 1 | 2018 | 1338 | 0.47 | Why? |
| Carcinoma, Squamous Cell | 5 | 2018 | 902 | 0.44 | Why? |
| Biological Specimen Banks | 1 | 2018 | 1142 | 0.41 | Why? |
| Salivary Gland Neoplasms | 2 | 2019 | 25 | 0.36 | Why? |
| Thyroglobulin | 2 | 2018 | 39 | 0.36 | Why? |
| Immunohistochemistry | 6 | 2018 | 2275 | 0.36 | Why? |
| Oropharyngeal Neoplasms | 3 | 2018 | 138 | 0.34 | Why? |
| Autopsy | 1 | 2017 | 3495 | 0.31 | Why? |
| Lymphatic Metastasis | 5 | 2018 | 537 | 0.30 | Why? |
| NF-E2-Related Factor 2 | 2 | 2019 | 373 | 0.29 | Why? |
| Epithelial Cells | 1 | 2017 | 3508 | 0.28 | Why? |
| Suicide | 1 | 2017 | 1500 | 0.27 | Why? |
| Lymph Nodes | 3 | 2018 | 1060 | 0.25 | Why? |
| Submandibular Gland | 2 | 2019 | 29 | 0.24 | Why? |
| Proto-Oncogene Proteins c-ret | 2 | 2018 | 15 | 0.22 | Why? |
| Papillomavirus Infections | 3 | 2018 | 861 | 0.21 | Why? |
| Head and Neck Neoplasms | 3 | 2018 | 1568 | 0.21 | Why? |
| GTP Phosphohydrolases | 2 | 2017 | 89 | 0.21 | Why? |
| Kidney Transplantation | 1 | 2020 | 5397 | 0.21 | Why? |
| Selenoproteins | 1 | 2019 | 29 | 0.20 | Why? |
| Membrane Proteins | 3 | 2019 | 1733 | 0.19 | Why? |
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2018 | 4 | 0.19 | Why? |
| Atypical Squamous Cells of the Cervix | 1 | 2018 | 5 | 0.19 | Why? |
| Diagnosis, Differential | 3 | 2018 | 7220 | 0.19 | Why? |
| Jumonji Domain-Containing Histone Demethylases | 1 | 2018 | 28 | 0.19 | Why? |
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2018 | 46 | 0.19 | Why? |
| Microsatellite Instability | 1 | 2018 | 57 | 0.19 | Why? |
| Hashimoto Disease | 1 | 2019 | 74 | 0.19 | Why? |
| Nipecotic Acids | 1 | 2017 | 2 | 0.18 | Why? |
| Humans | 46 | 2021 | 930598 | 0.18 | Why? |
| Liquid Biopsy | 1 | 2019 | 114 | 0.18 | Why? |
| Enterobius | 1 | 2017 | 2 | 0.18 | Why? |
| Neoplasms, Experimental | 1 | 2018 | 67 | 0.18 | Why? |
| Melphalan | 1 | 2017 | 46 | 0.18 | Why? |
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2017 | 31 | 0.18 | Why? |
| Anterior Chamber | 1 | 2017 | 26 | 0.18 | Why? |
| Patched Receptors | 1 | 2017 | 2 | 0.18 | Why? |
| Hyalin | 1 | 2017 | 4 | 0.18 | Why? |
| Antineoplastic Agents, Alkylating | 1 | 2017 | 71 | 0.18 | Why? |
| Retinoblastoma | 1 | 2017 | 41 | 0.17 | Why? |
| Parathyroid Hormone | 1 | 2017 | 98 | 0.17 | Why? |
| Retinal Neoplasms | 1 | 2017 | 45 | 0.17 | Why? |
| Postmortem Changes | 1 | 2017 | 133 | 0.17 | Why? |
| Gene Rearrangement | 1 | 2017 | 84 | 0.17 | Why? |
| Cysts | 1 | 2018 | 94 | 0.17 | Why? |
| Thiophenes | 1 | 2017 | 78 | 0.17 | Why? |
| Neoplasm Grading | 1 | 2018 | 400 | 0.17 | Why? |
| Parotid Gland | 1 | 2016 | 53 | 0.17 | Why? |
| Iodine | 1 | 2018 | 116 | 0.16 | Why? |
| Forensic Pathology | 1 | 2017 | 109 | 0.16 | Why? |
| Spectrum Analysis, Raman | 1 | 2018 | 311 | 0.16 | Why? |
| Lymphatic Vessels | 1 | 2016 | 43 | 0.16 | Why? |
| Biochemistry | 1 | 2017 | 86 | 0.15 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.15 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.15 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 3633 | 0.15 | Why? |
| Calcitonin | 1 | 2017 | 201 | 0.15 | Why? |
| Laboratories, Hospital | 1 | 2020 | 489 | 0.15 | Why? |
| Homeodomain Proteins | 1 | 2016 | 93 | 0.15 | Why? |
| Pathology, Clinical | 1 | 2020 | 407 | 0.15 | Why? |
| Tumor Burden | 1 | 2017 | 369 | 0.15 | Why? |
| Pyriform Sinus | 1 | 2014 | 16 | 0.14 | Why? |
| Tumor Suppressor Proteins | 1 | 2016 | 165 | 0.14 | Why? |
| Fluorine Radioisotopes | 1 | 2014 | 59 | 0.14 | Why? |
| Vagina | 1 | 2017 | 327 | 0.14 | Why? |
| Neovascularization, Pathologic | 1 | 2018 | 305 | 0.14 | Why? |
| Hypopharyngeal Neoplasms | 1 | 2014 | 47 | 0.14 | Why? |
| Pathology, Molecular | 1 | 2017 | 343 | 0.14 | Why? |
| Mutation | 3 | 2019 | 12376 | 0.13 | Why? |
| Virus Shedding | 2 | 2021 | 5834 | 0.13 | Why? |
| Endocrine System Diseases | 1 | 2017 | 282 | 0.13 | Why? |
| Colonic Neoplasms | 1 | 2017 | 295 | 0.12 | Why? |
| Mouth Neoplasms | 2 | 2018 | 463 | 0.12 | Why? |
| Incidental Findings | 1 | 2017 | 487 | 0.12 | Why? |
| Neoplasm Proteins | 1 | 2018 | 501 | 0.12 | Why? |
| Antidepressive Agents | 1 | 2018 | 509 | 0.12 | Why? |
| Proto-Oncogene Proteins B-raf | 3 | 2019 | 179 | 0.12 | Why? |
| Papillomavirus Vaccines | 1 | 2017 | 405 | 0.12 | Why? |
| Female | 23 | 2021 | 380317 | 0.12 | Why? |
| Ontario | 1 | 2018 | 1966 | 0.11 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.11 | Why? |
| Bone Neoplasms | 1 | 2014 | 287 | 0.11 | Why? |
| Neoplasm Recurrence, Local | 1 | 2018 | 1063 | 0.10 | Why? |
| Recurrence | 1 | 2020 | 3675 | 0.10 | Why? |
| Workload | 1 | 2020 | 1887 | 0.10 | Why? |
| Male | 21 | 2021 | 367725 | 0.10 | Why? |
| Adult | 13 | 2021 | 244371 | 0.10 | Why? |
| Radiopharmaceuticals | 1 | 2014 | 763 | 0.09 | Why? |
| Diagnostic Tests, Routine | 1 | 2021 | 2643 | 0.09 | Why? |
| Follow-Up Studies | 4 | 2020 | 17020 | 0.09 | Why? |
| Robotic Surgical Procedures | 1 | 2017 | 787 | 0.09 | Why? |
| Antioxidants | 1 | 2018 | 1593 | 0.09 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.09 | Why? |
| Proto-Oncogene Proteins p21(ras) | 2 | 2019 | 100 | 0.09 | Why? |
| Italy | 3 | 2021 | 38444 | 0.09 | Why? |
| Prognosis | 7 | 2021 | 32490 | 0.09 | Why? |
| Japan | 1 | 2021 | 6653 | 0.09 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2014 | 1153 | 0.08 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2019 | 3607 | 0.08 | Why? |
| ErbB Receptors | 2 | 2019 | 320 | 0.08 | Why? |
| Gastrointestinal Diseases | 1 | 2021 | 2580 | 0.07 | Why? |
| Aged | 13 | 2021 | 215776 | 0.07 | Why? |
| Promoter Regions, Genetic | 2 | 2019 | 823 | 0.07 | Why? |
| Asymptomatic Diseases | 1 | 2017 | 3444 | 0.07 | Why? |
| Retrospective Studies | 8 | 2020 | 105322 | 0.07 | Why? |
| Dendritic Cells, Follicular | 1 | 2003 | 3 | 0.07 | Why? |
| Neoplasm Invasiveness | 2 | 2017 | 582 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2019 | 4027 | 0.07 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2014 | 1458 | 0.07 | Why? |
| Mice, Inbred C57BL | 3 | 2019 | 5542 | 0.06 | Why? |
| Immunotherapy | 1 | 2017 | 2421 | 0.06 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.06 | Why? |
| Renal Dialysis | 1 | 2020 | 4358 | 0.06 | Why? |
| Papillomaviridae | 2 | 2017 | 404 | 0.06 | Why? |
| Lymphocytes, Tumor-Infiltrating | 1 | 2003 | 130 | 0.06 | Why? |
| Carcinoma, Bronchogenic | 1 | 2002 | 5 | 0.06 | Why? |
| Receptors, Estrogen | 1 | 2003 | 171 | 0.06 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.06 | Why? |
| Pleural Effusion, Malignant | 1 | 2002 | 37 | 0.06 | Why? |
| Europe | 1 | 2018 | 12702 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.05 | Why? |
| Intraoperative Complications | 1 | 2002 | 221 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.05 | Why? |
| Iodides | 1 | 2018 | 10 | 0.05 | Why? |
| PAX8 Transcription Factor | 1 | 2018 | 7 | 0.05 | Why? |
| Switzerland | 2 | 2017 | 2738 | 0.05 | Why? |
| Kelch-Like ECH-Associated Protein 1 | 1 | 2018 | 21 | 0.05 | Why? |
| Cell Line, Tumor | 2 | 2018 | 3608 | 0.05 | Why? |
| Survival Rate | 3 | 2018 | 9206 | 0.05 | Why? |
| Mice | 4 | 2019 | 21357 | 0.05 | Why? |
| Mice, Inbred NOD | 1 | 2018 | 134 | 0.05 | Why? |
| ras Proteins | 1 | 2018 | 37 | 0.05 | Why? |
| Microscopy, Acoustic | 1 | 2017 | 20 | 0.05 | Why? |
| Receptors, Notch | 1 | 2018 | 59 | 0.05 | Why? |
| Animals | 5 | 2019 | 78931 | 0.04 | Why? |
| Mice, SCID | 1 | 2018 | 225 | 0.04 | Why? |
| Tissue Array Analysis | 1 | 2017 | 75 | 0.04 | Why? |
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 43 | 0.04 | Why? |
| Preoperative Period | 1 | 2018 | 271 | 0.04 | Why? |
| International Agencies | 1 | 2019 | 202 | 0.04 | Why? |
| Nausea | 1 | 2021 | 457 | 0.04 | Why? |
| Risk Assessment | 2 | 2019 | 25439 | 0.04 | Why? |
| Keratinocytes | 1 | 2018 | 119 | 0.04 | Why? |
| Biopsy, Needle | 1 | 2018 | 303 | 0.04 | Why? |
| PPAR gamma | 1 | 2018 | 102 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Cytoplasm | 1 | 2018 | 304 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2019 | 11304 | 0.04 | Why? |
| Margins of Excision | 1 | 2017 | 122 | 0.04 | Why? |
| Chlamydia trachomatis | 1 | 2017 | 172 | 0.04 | Why? |
| Tumor Microenvironment | 1 | 2018 | 264 | 0.04 | Why? |
| Radiotherapy, Adjuvant | 1 | 2017 | 180 | 0.04 | Why? |
| Medical Records | 1 | 2019 | 513 | 0.04 | Why? |
| Thyroid Hormones | 1 | 2018 | 213 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2021 | 14232 | 0.04 | Why? |
| Vomiting | 1 | 2021 | 722 | 0.04 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.04 | Why? |
| Haplotypes | 1 | 2019 | 853 | 0.04 | Why? |
| Oxidation-Reduction | 1 | 2018 | 540 | 0.04 | Why? |
| Adolescent | 4 | 2019 | 86841 | 0.04 | Why? |
| Salvage Therapy | 1 | 2017 | 417 | 0.04 | Why? |
| Chlamydia Infections | 1 | 2017 | 248 | 0.04 | Why? |
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 347 | 0.04 | Why? |
| Chemoradiotherapy | 1 | 2017 | 362 | 0.04 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.03 | Why? |
| Homeostasis | 1 | 2018 | 582 | 0.03 | Why? |
| Neoplasm Metastasis | 1 | 2016 | 682 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Mice, Knockout | 1 | 2018 | 1815 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| Analysis of Variance | 1 | 2016 | 950 | 0.03 | Why? |
| Lung Neoplasms | 2 | 2016 | 3228 | 0.03 | Why? |
| Gene Frequency | 1 | 2017 | 1210 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2018 | 1136 | 0.03 | Why? |
| Cell Line | 2 | 2018 | 12040 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.03 | Why? |
| Mouth | 1 | 2016 | 622 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Health Facilities | 1 | 2019 | 1230 | 0.03 | Why? |
| Rats | 1 | 2018 | 2764 | 0.03 | Why? |
| Neoplasms | 1 | 2019 | 17251 | 0.03 | Why? |
| Urinary Bladder Neoplasms | 1 | 2016 | 614 | 0.03 | Why? |
| Neoplasm Staging | 1 | 2016 | 1999 | 0.02 | Why? |
| Diarrhea | 1 | 2021 | 2743 | 0.02 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.02 | Why? |
| Kidney Neoplasms | 1 | 2016 | 832 | 0.02 | Why? |
| Cells, Cultured | 1 | 2019 | 5835 | 0.02 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.02 | Why? |
| Oxidative Stress | 1 | 2018 | 2050 | 0.02 | Why? |
| Risk | 1 | 2019 | 5288 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Infant | 2 | 2019 | 30274 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2016 | 5440 | 0.02 | Why? |
| Child | 3 | 2019 | 70012 | 0.02 | Why? |
| Fatal Outcome | 1 | 2014 | 3438 | 0.02 | Why? |
| Oxygen | 1 | 2018 | 3715 | 0.02 | Why? |
| Child, Preschool | 2 | 2019 | 36283 | 0.02 | Why? |
| Estrogen Antagonists | 1 | 2003 | 36 | 0.02 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.02 | Why? |
| Prostatic Neoplasms | 1 | 2016 | 1637 | 0.02 | Why? |
| Receptors, Progesterone | 1 | 2003 | 76 | 0.02 | Why? |
| Estrogen Receptor alpha | 1 | 2003 | 40 | 0.02 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.02 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.02 | Why? |
| Hyperplasia | 1 | 2003 | 204 | 0.02 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.02 | Why? |
| Tamoxifen | 1 | 2003 | 83 | 0.02 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.01 | Why? |
| Tissue Distribution | 1 | 2003 | 483 | 0.01 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Immunophenotyping | 1 | 2003 | 1290 | 0.01 | Why? |
| Prevalence | 1 | 2021 | 25773 | 0.01 | Why? |
| Breast Neoplasms | 1 | 2016 | 3633 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 11367 | 0.01 | Why? |
| Young Adult | 2 | 2019 | 93724 | 0.01 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.01 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Treatment Outcome | 1 | 2017 | 51732 | 0.01 | Why? |
| RNA, Messenger | 1 | 2003 | 5131 | 0.01 | Why? |
| Survival Analysis | 1 | 2002 | 7592 | 0.01 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.01 | Why? |
| Biomarkers | 1 | 2003 | 23361 | 0.00 | Why? |